Software for laboratories where the sample belongs to someone: why biobank software has to hold consent scope and chain of custody against every vial rather than merely locating it, what automation in clinical laboratory work, clinical lab automation and automation clinical laboratory projects change about the informatics rather than the bench, where clinical laboratory equipment, clinical lab equipment purchasing and clinical laboratory supplies decisions are constrained by the accreditation the laboratory holds, how batch record review, molecular quality control and product stability testing turn records into evidence somebody can rely on, what bioanalytical testing has to deliver into a study file, and where clinical trial monitoring, clinical trial site support, clinical trial patient support and clinical trial patient recruitment or patient recruitment clinical trial work sit as operational rather than laboratory functions

Specifying the system

1. Start from the duties, not the features. Consent scope, custody, retention and attributable records are obligations. List them first and use them to shortlist, because most products demonstrate convenience features and leave the duties to be discovered later.
2. Map the custody chain on paper. Every point where material changes hands, is split or is destroyed, and who records it. Points where nobody records anything are requirements, and they are where audits find problems.
3. Decide what review has to be evidenced. Batch record review and quality control approval have to be visible in the record with who did it and when. A system that allows review without recording it does not support the process.
4. Check the audit trail by exporting one. Ask to export an audit trail from a live system during evaluation. It is far more informative about a product's fitness than any demonstration of the interface.
5. Separate laboratory from operational scope. Trial monitoring, site support and recruitment are operational functions with their own systems. Trying to run them from a laboratory system produces a poor fit in both directions.
6. Settle export before signing. Format, whether the audit trail is included, whether attachments retain metadata, and whether it can be done without the supplier. It is the clause that matters most later and is negotiated least now.

Consent travels with the material

A vial from a person carries the scope of what that person agreed to, and a use outside it is not fixable afterwards. Holding that scope in the system, against the material rather than in a filing cabinet, is what makes it operable.

Ask each vendor how consent scope is represented and how a query respects it. Products that treat it as a free text field are not solving the problem.

Implementation is the risk

Systems in this category rarely fail technically. They fail because migration was underestimated, the data model was configured to match an idealised process, or nobody owned the rollout.

Name an owner, budget their time, clean the existing records before migration, and run in parallel for a defined period with a decided cutover.

Common questions

Is a biobank system just a sample tracker?

No. It adds consent scope, chain of custody, retention and destruction control and attributable records. A research tracker with those bolted on is usually a poor fit, and the gap appears at the first audit.

What does clinical laboratory automation actually change?

Mostly the informatics: specimen routing, result capture, autoverification rules and the audit of those rules. The mechanical part is the visible half and the smaller problem.

How is review evidenced?

By a record showing who reviewed what and when, unalterable afterwards, tied to the batch or result. A signature on a printout is weaker and a review with no record is not a review.

Browse by service class

• Compare Gene synthesis on advertised prices